E31.21
Multiple endocrine neoplasia [MEN] type I
Clinical Classification Guidelines
Inclusion Terms
- Wermer's syndrome
Medical Intelligence & Overview
Multiple Endocrine Neoplasia Type I (MEN I), also known as Wermer's syndrome, is a hereditary condition characterized by the development of tumors in multiple endocrine glands. These tumors can be benign or malignant and often affect the parathyroid glands, pancreas, and pituitary gland. Recognizing and managing MEN I is important because it can lead to various health issues if left untreated. This condition is inherited in an autosomal dominant pattern, which means a person with the mutation has a significant chance of passing it on to their children.
Causes & Symptoms
Clinical Causes: Genetic mutations, specifically in the MEN1 gene, which encodes the protein menin Inheritance pattern: autosomal dominant Family history of endocrine tumors Potential environmental factors are not well established but may influence the expression Genetic counseling recommended for individuals with a family history
Key Symptoms: Hypercalcemia symptoms from overactive parathyroid glands, such as osteoporosis, kidney stones, abdominal pain, and fatigue Hormonal imbalances caused by pancreatic tumors, leading to symptoms like frequent blood sugar fluctuations, diarrhea, and abdominal discomfort Pituitary tumors can cause headaches, visual disturbances, or hormonal deficiencies, such as reduced growth hormone or prolactin levels General signs include fatigue, unexplained weight changes, or symptoms related to specific gland involvement Some individuals may remain asymptomatic for many years and only discover the condition through screening
Diagnostic & Treatment
Diagnosis Path: Diagnosis of MEN I involves a combination of clinical evaluation, family history, and laboratory testing. Key diagnostic steps include: - Blood tests to measure hormone levels, such as calcium, parathyroid hormone, insulin, gastrin, and prolactin - Imaging studies, including MRI or CT scans, to identify tumors in the affected glands - Genetic testing to detect mutations in the MEN1 gene - Regular screening in individuals with a family history to identify tumors early and monitor progression - Biochemical testing for specific hormones produced by endocrine tumors to aid in localization and characterization
Treatment Protocols: Management of MEN I focuses on controlling symptoms, treating tumors, and preventing complications. Treatment options may include: - Surgical removal of overactive or tumor-bearing glands, such as parathyroidectomy or pancreatic tumor removal - Medications to control hormone levels, such as proton pump inhibitors or hormone therapies - Regular follow-up with endocrinologists for ongoing monitoring - Targeted therapies or chemotherapy if tumors are malignant or unresectable - Genetic counseling for affected families to understand risks and screening options - Lifestyle modifications and supportive care to manage symptoms and improve quality of life It is important for individuals with MEN I to undergo lifelong surveillance to detect new tumors early and to manage existing conditions effectively.
Clinical Advice & FAQs
Billing Guidance
Is E31.21 a billable ICD-10 code?
Yes, E31.21 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E31.21?
Clinical documentation must specify the nature of Multiple endocrine neoplasia [MEN] type I and any associated comorbidities for accurate reporting.
Cite this Clinical Reference